Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 1;18(1):22.
doi: 10.1186/s12886-018-0690-9.

Influence of new societal factors on neovascular age-related macular degeneration outcomes

Audrey Giocanti-Aurégan  1   2 , Elige Chbat  3 , Adil Darugar  4   5 , Christophe Morel  3 , Bruno Morin  3 , John Conrath  3 , François Devin  3
Affiliations

Influence of new societal factors on neovascular age-related macular degeneration outcomes

Audrey Giocanti-Aurégan et al. BMC Ophthalmol. .

Abstract

Background: To assess the impact of unstudied societal factors for neovascular age-related macular degeneration (nAMD) on functional outcomes after anti-VEGFs.

Methods: Charts of 94 nAMD patients treated in the Monticelli-Paradis Centre, Marseille, France, were reviewed. Phone interviews were conducted to assess societal factors, including transportation, living status, daily reading and social security scheme (SSS). Primary outcome was the impact of family support and disease burden on functional improvement in nAMD.

Results: Between baseline and month 24 (M24), 42.4% of the variability in best-corrected visual acuity (BCVA) was explained by the cumulative effect of the following societal factors: intermittent out-patient follow-up, marital status, daily reading, transportation type, commuting time. No isolated societal factor significantly correlated with ETDRS BCVA severity at M24. A trend to correlation was observed between the EDTRS score at M24 and the SSS (P = 0.076), economic burden (P = 0.075), time between diagnosis and treatment initiation (P = 0.070). A significant correlation was found for the disease burdensome on the patient (P = 0.034) and low vision rehabilitation (P = 0.014).

Conclusions: Societal factors could influence functional outcomes in nAMD patients treated with anti-VEGFs. They could contribute to the healing process or sustain disease progression.

Keywords: Age-related macular degeneration; Economic burden; Retinal disease; Societal factors.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This study was conducted in accordance with the tenets of the Declaration of Helsinki, and an informed consent was obtained from subjects. Approval was obtained from the France Macula Federation ethical committee.

Consent for publication

An informed consent was obtained from the patient.

Competing interests

Audrey Giocanti-Aurégan is consultant for Alimera, Allergan, Bayer and Novartis. Adil Darugar is consultant for Bayer and Novartis. Elige Chbat has nothing to disclose. François Devin, Christophe Morel, Bruno Morin are consultants for Alimera, Allergan, Bayer and Novartis, Roche, Ophtotec, Thea, Alcon, Zeiss. John Conrath is consultant for Alimera, Allergan, Bayer and Novartis, Roche, Ellex, Alcon.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Graphical representation of the model assessing the weight (coefficient) of each variable on the change in ETRDS score over 24 months
Fig. 2
Fig. 2
Graphical representation of the model assessing the weight (coefficient) of each variable on the change in ETRDS score over 24 months in the subgroup of nAMD patients who gained vision over 24 months
Fig. 3
Fig. 3
Graphical representation of the model assessing the weight (coefficient) of each variable on the change in ETRDS score over 24 months in the subgroup of nAMD patients who lost vision over 24 months
See this image and copyright information in PMC

References

    1. Klein R, Klein BE, Cruickshanks KJ. The prevalence of age-related maculopathy by geographic region and ethnicity. Prog Retin Eye Res. 1999;18:371–389. doi: 10.1016/S1350-9462(98)00025-1. - DOI - PubMed
    1. Mitchell P, Smith W, Attebo K, Wang JJ. Prevalence of age-related maculopathy in Australia. The Blue Mountains eye study. Ophthalmology. 1995;102:1450–1460. doi: 10.1016/S0161-6420(95)30846-9. - DOI - PubMed
    1. Klaver CC, Assink JJ, van Leeuwen R, Wolfs RC, Vingerling JR, Stijnen T, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam study. Invest Ophthalmol Vis Sci. 2001;42:2237–2241. - PubMed
    1. Kawasaki R, Yasuda M, Song SJ, Chen S-J, Jonas JB, Wang JJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117:921–927. doi: 10.1016/j.ophtha.2009.10.007. - DOI - PubMed
    1. Wong TY, Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115:116–126. doi: 10.1016/j.ophtha.2007.03.008. - DOI - PubMed

MeSH terms

LinkOut - more resources